Hypertension is frequent in patients with atrial fibrillation (AF) and is an independent risk
factor for stroke. The Randomized Evaluation of Long Term Anticoagulant TherapY (RE-LY) …

Background Patients with valvular heart disease (VHD) were allowed into the RE-LY® trial if
their VHD was considered unlikely to result in an intervention before study completion or if …

Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases
the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …

Background: RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an
international multicenter study (18,113 patients from 967 centers in 44 countries) that …

The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for
stroke prevention in non-valvular atrial fibrillation. It is important to further evaluate safety …

This is the first evaluation of dabigatran, an oral direct thrombin inhibitor, in patients with
atrial fibrillation (AF). Patients (n= 502) were randomized to receive blinded doses of 50 …

Atrial fibrillation (AF) is the most common sustained cardiac rhythm disturbance found in
clinical practice, increasing in prevalence with age. AF is often associated with structural …

Background—During follow-up of between 1 and 3 years in the Randomized Evaluation of
Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were …

This article has been corrected. The original version (PDF) is appended to this article as a
Supplement. Background: Dabigatran (150 mg twice daily) has been associated with lower …

Objectives: This study sought to compare the net clinical benefit of dabigatran 110 mg bid
and 150 mg bid with that of warfarin in patients with atrial fibrillation (AF). Background: In …